Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFLECT-1 rosiglitazone XR monotherapy in APOE ε4-stratified mild to moderate Alzheimer's disease
2006-002038-39Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Rosiglitazone XR monotherapy, Donepezil monotherapy and Placebo (3 arms). Primary endpoint: Change from baseline in ADAS-Cog total score at Week 24. Started Nov 2006; status: completed.
02
Drugs
rosiglitazonedonepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-002038-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002038-39.